Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Inserm
Sponsor

Inserm

France 101 Rue De Tolbiac, 75013 Paris, France

About the sponsor

Research activity includes Alzheimer's disease, Lewy body dementia, Parkinson's disease, prodromal Parkinson's disease, semantic variant primary progressive aphasia, organic amnesia syndrome, and memory disorders across different clinical presentations. The funded studies use PET imaging, MRI, and functional neuroimaging to examine tau pathology, serotonergic dysfunction, microglial activation, and memory network integrity.

  • Alzheimer's pathology
  • Parkinson's disease biomarkers
  • Neuroinflammation and tau imaging
  • Memory network organisation

Additional work spans comatose traumatic brain injury and dopaminergic pathway abnormalities linked to recovery assessment.

About Specializations

Inserm runs clinical trials in conditions such as HIV infection, Dementia Alzheimer's type, COVID-19, Schizophrenia, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

13 clinical trials

Dementia Alzheimer's type

Recruiting

Study of flortaucipir and florbetapir in patients with memory disorders including Alzheimer's disease and dementia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Florbetapir (18F)
  • Sponsor:Inserm

Schizophrenia

Recruiting

Study on Brain Inflammation in Schizophrenia Patients Using 18F-DPA-714

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
  • Sponsor:Inserm

COVID-19

Recruiting

Study comparing intranasal COVID-19 vaccine (LVT-001) with mRNA vaccine (bretovameran) as booster doses in healthy adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:Bretovameran
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Craniocerebral injury

Recruiting

Study on Dopaminergic Pathway Disruption in Comatose Patients with Traumatic Brain Injury Using [18F]LBT-999

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Inserm

Epidermolysis bullosa

Recruiting

Study on Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa Using Skin Grafts with Genetically Corrected Autologous Keratinocytes and Fibroblasts

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS KERATINOCYTES AND FIBROBLASTS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING COL7A1 CDNA
  • Sponsor:Inserm

HIV infection

Recruiting

Study Comparing Doravirine and Dolutegravir-Based Treatments for People with HIV-1 Who Have Not Yet Started Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dolutegravir Sodium
  • Sponsor:Inserm

HIV infection+1

Recruiting

Study on Reducing HIV-HBV Treatment with Darunavir, Ritonavir, and Lamivudine for Patients with Controlled Co-Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Darunavir
  • Sponsor:Inserm

Alcoholism

Not yet recruiting

Effect of Hydroxocobalamin Acetate, Thiamine Hydrochloride, and Pyridoxine Hydrochloride Supplementation on Brain Injury in Outpatients with Alcohol Use Disorder

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Pyridoxine Hydrochloride
  • Sponsor:Inserm

Parkinson's disease+1

Not yet recruiting

Study of serotonin system changes in early Parkinson's disease using [11C]DASB and [11C]SB207145 PET imaging in people with SNCA gene mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:(1-(11C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE
  • Sponsor:Inserm

Dementia Alzheimer's type

Not yet recruiting

Study on Brain Changes in Alzheimer's Disease Using Flortaucipir (18F) for Patients with Alzheimer's and Its Variants

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Flortaucipir (18F)
  • Sponsor:Inserm

HIV infection

Not recruiting

Study of Injectable Cabotegravir Compared to Oral Emtricitabine/Tenofovir for HIV Prevention in Men Who Have Sex with Men

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Inserm

Sarcoma

Not recruiting

Study on Advanced Soft-Tissue Sarcoma: Testing Futibatinib and Drug Combination for Patients with Unresectable or Metastatic Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capmatinib
  • Sponsor:Inserm

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.